Cargando…
SLCO4C1 promoter methylation is a potential biomarker for prognosis associated with biochemical recurrence-free survival after radical prostatectomy
BACKGROUND: Prostate cancer (PC) is a commonly diagnosed malignancy in males, especially in the western hemisphere. The extensive use of multiple biomarkers plays an important role in the diagnosis and prognosis of PC. However, the accuracy of biomarkers for PC prognosis needs to be urgently improve...
Autores principales: | Li, Xin, Zhang, Wanfeng, Song, Jing, Zhang, Xianqin, Ran, Longke, He, Yunfeng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6617673/ https://www.ncbi.nlm.nih.gov/pubmed/31288850 http://dx.doi.org/10.1186/s13148-019-0693-2 |
Ejemplares similares
-
The Prognostic Factors of Biochemical Recurrence-Free Survival Following Radical Prostatectomy
por: Chalieopanyarwong, Virote, et al.
Publicado: (2017) -
PITX3 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients after radical prostatectomy
por: Holmes, Emily Eva, et al.
Publicado: (2016) -
Biochemical Recurrence-Free and Cancer-Specific Survival after Radical Prostatectomy at a Single Institution
por: Kim, Seong Cheol, et al.
Publicado: (2010) -
High expression of SLCO2B1 is associated with prostate cancer recurrence after radical prostatectomy
por: Terakawa, Tomoaki, et al.
Publicado: (2018) -
Aberrant Methylation of PCDH10 Predicts Worse Biochemical Recurrence-Free Survival in Patients with Prostate Cancer After Radical Prostatectomy
por: Wang, Li, et al.
Publicado: (2014)